This dual role of immunomodulation and intrinsic tumor suppression makes LAG3 distinct from PD‐1/CTLA‐4 and may explain the association of anti‐PD‐1 resistance with LAG3/FGL1 co‐expression [45]. The gene discussed is CTLA4; the disease is neoplasm.